Aimeike (300896.SZ) plans to transfer 10 shares to 4 shares and send 23.23 yuan to cut interest on April 29

Ameke (300896.SZ) announced that the company plans to pay 23.23 yuan (tax included) for every 10 shares to all shareholders,...

Zhitong FinanceApr 19 20:10

Jinbo Biotech's performance is rising, and founder Yang Xia is the richest woman in Shanxi

In the eyes of familiar people, this “scientist with a tough style of work” is releasing energy in the capital market.

lanjinger.comApr 17 22:23

The actual controllers of Ameke have made a profit, but what about shareholders?

“Investor Network” How profitable can a Jordan woman's face business be? From 2014 to 2023, Aimeike (300896.SZ), a “women's Maotai”, achieved leaps and bounds in performance by relying on products with a unit cost of only 20 to 30 yuan. The revenue scale increased from 75 million yuan to 2.9 billion yuan, and net profit also climbed from 28 million yuan to 1.9 billion yuan. Although the beautiful economy is attractive, the capital market is not an easy path. Aimeike went public with an overfunding of 1.5 billion yuan. At the beginning of its listing, it was enthusiastically sought after by the market, but now its market value has shrunk drastically, falling to more than 220 billion yuan. Not listed

China InvestorsApr 17 07:31

Quarterly Report | Hard to find the next “Good Body”, Aimeike's performance growth is slowing down

Aimee faces pressure from many other competitors.

lanjinger.comApr 12 15:31

Aimeike (300896): Wet White Angel is growing steadily, and a multi-matrix relay growth

Aimeike released a preview for 1Q24. It is estimated that 1Q24 revenue will be 80,000-83%, up 27.5%-31% year on year, and net profit to mother will be 51-53 million yuan, up 23%-29% year on year. Benefit from medical and aesthetic medicine

海通證券Apr 12 07:36

Aimeike (300896.SZ): Pre-increase non-net profit by more than 30% in 2024Q1, forward-looking layout of the Blue Ocean Circuit

Aimeike, known as the “medical beauty”, seems to have recently faced quite a few challenges in the A-share market. Since April, its stock price has retreated nearly 15%, and its PE (TTM) has fallen to 34.67 times, setting a new low since listing. Naturally, this situation has attracted widespread attention in the market. (Data closes on April 9) However, when we delved deeper into the company's recently released earnings data, we saw a different picture. According to the 2023 annual report and the forecast for the first quarter of 2024, Aimec showed a steady growth trend. In 2023, the company achieved revenue of 2,869 billion yuan

Gelonghui FinanceApr 11 08:41